SCPH options cashed out; CVRs issued with up to $1.00 payout
Rhea-AI Filing Summary
scPharmaceuticals insider transactions tied to merger consideration: The reporting person, Leonard D. Schaeffer, reported that on 10/07/2025 non‑derivative holdings totaling 111,900 shares were disposed (68,796 direct; 43,104 indirect) in connection with a completed tender offer and merger. Tendering shareholders received $5.35 per share in cash plus one non‑tradable contingent value right (CVR) that may pay up to $1.00 per CVR upon achievement of specified regulatory and net‑sales milestones. Outstanding stock options with exercise prices below $5.35 were cancelled and converted into cash payments and one CVR per underlying share; the reporting person’s affected options totaling 66,050 (30,000; 19,750; 16,300) were reported as disposed.
Positive
- Cash consideration of $5.35 per share provided liquidity to tendering stockholders
- CVRs issued create a contingent upside of up to $1.00 per CVR tied to clear milestones
- Options in‑the‑money were monetized by cash payments equal to intrinsic value
Negative
- Reporting person holds 0 common shares post‑transaction, eliminating direct share exposure
- 66,050 option rights cancelled, removing future upside from those grants absent CVR payouts
- CVR value is contingent on regulatory and net‑sales milestones and may pay nothing if milestones are unmet
Insights
Transaction aligns with merger closing and standard payout mechanics.
The filing shows a director disposed of both direct and indirectly held common shares as part of a tender offer and resulting merger, receiving $5.35 per share plus CVRs. The report documents the post‑transaction ownership at 0 shares for the reporting person, consistent with a full tender/merger exit.
Key dependencies are the CVR milestone triggers and related payment timing; investors should note the CVR pays up to $1.00 only if specified regulatory and net‑sales conditions occur on or before their milestone outside dates.
In‑the‑money options were cashed out and converted to CVRs per the merger agreement.
Options with exercise prices below $5.35 were cancelled and replaced by a cash payment equal to the intrinsic spread and one CVR per share underlying each option. The filing lists cancellations of 30,000, 19,750, and 16,300 option grants totaling 66,050 underlying shares.
The material follow‑up is the actual CVR payouts if milestones are met; timing and likelihood of those regulatory and sales milestones determine any incremental value beyond the $5.35 cash already paid.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 19,750 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 16,300 | $0.00 | -- |
| U | Common Stock | 68,796 | $0.00 | -- |
| U | Common Stock | 43,104 | $0.00 | -- |
Footnotes (1)
- In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
